Author + information
- Stephanie Mattathil,
- Saad Sultan Ghumman,
- Jonathan Weinerman and
- Anand Prasad
Background: Contrast induced kidney injury (CI-AKI) following cardiovascular interventions results in increased morbidity and mortality. RenalGuard (RG) is a novel, closed loop system which balances volume administration with forced diuresis to maintain a high urine output. We performed a meta-analysis of the existing data comparing use of RG to conventional volume expansion.
Methods: 9 studies were found eligible, of which 6 were randomized controlled trials utilizing RG in various cardiovascular diagnostic and therapeutic interventions. Primary outcomes included CI-AKI incidence and relative risk. Mortality, dialysis and major adverse cardiovascular events (MACCE) were secondary outcomes. A fixed effects model was used and data was evaluated for publication bias.
Results: RG was associated with significant risk reduction in CI-AKI compared to control (RR: 0.409; 95% CI: 0.282-0.591; p <0.001). The study results were homogenous with presence of potential publication bias. CI-AKI in RG was found to be 8.7% versus 23% in the control group (p<0.001). Use of RG was associated with decreased mortality (RR 0.425, 95% CI: 0.183- 0.987, p = 0.047), dialysis (RR 0.197; 95% CI 0.063-0.614, p=0.005) and MACCE (RR 0.421, 95% CI: 0.273-0.651, p<0.001) compared to standard hydration.
Conclusions: RG significantly reduces rates of CI-AKI compared to standard volume expansion and is also associated with decreased rates of death, MACCE and dialysis.
Poster Hall, Hall C
Sunday, March 19, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Interventional Complexity and Complications
Abstract Category: 26. Interventional Cardiology: Vascular Access and Complications
Presentation Number: 1285-161
- 2017 American College of Cardiology Foundation